Specialized proresolving mediators in infection and lung injury.
Biofactors
; 47(1): 6-18, 2021 Jan.
Article
in English
| MEDLINE | ID: covidwho-950385
ABSTRACT
Specialized proresolving mediators (SPMs) are endogenous lipid metabolites of long-chain polyunsaturated fatty acids that are involved in promoting the resolution of inflammation. Many disease conditions characterized by excessive inflammation have impaired or altered SPM biosynthesis, which may lead to chronic, unresolved inflammation. Exogenous administration of SPMs in infectious conditions has been shown to be effective at improving infection clearance and survival in preclinical models. SPMs have also shown tremendous promise in the context of inflammatory lung conditions, such as acute respiratory distress syndrome and chronic obstructive pulmonary disease, mostly in preclinical settings. To date, SPMs have not been studied in the context of the novel Coronavirus, severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), however their preclinical efficacy in combatting infections and improving acute respiratory distress suggest they may be a valuable resource in the fight against Coronavirus disease-19 (COVID-19). Overall, while the research on SPMs is still evolving, they may offer a novel therapeutic option for inflammatory conditions.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
Docosahexaenoic Acids
/
Pulmonary Disease, Chronic Obstructive
/
Lipoxins
/
Lung Injury
/
COVID-19 Drug Treatment
/
Anti-Inflammatory Agents
Type of study:
Prognostic study
Language:
English
Journal:
Biofactors
Journal subject:
Biochemistry
Year:
2021
Document Type:
Article
Affiliation country:
Biof.1691
Similar
MEDLINE
...
LILACS
LIS